MX2021001985A - Metodos agnosticos de conteo de plaquetas para tratar la mielofibrosis. - Google Patents

Metodos agnosticos de conteo de plaquetas para tratar la mielofibrosis.

Info

Publication number
MX2021001985A
MX2021001985A MX2021001985A MX2021001985A MX2021001985A MX 2021001985 A MX2021001985 A MX 2021001985A MX 2021001985 A MX2021001985 A MX 2021001985A MX 2021001985 A MX2021001985 A MX 2021001985A MX 2021001985 A MX2021001985 A MX 2021001985A
Authority
MX
Mexico
Prior art keywords
myelofibrosis
platelet count
methods
subject
momelotinib
Prior art date
Application number
MX2021001985A
Other languages
English (en)
Inventor
Barbara Jane Klencke
Gregg David Smith
Rafe Michael Joseph Donahue
Original Assignee
Sierra Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sierra Oncology Inc filed Critical Sierra Oncology Inc
Publication of MX2021001985A publication Critical patent/MX2021001985A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El nuevo análisis de los datos de los ensayos SIMPLIFY 1 y 2 indica que MMB es eficaz en pacientes sin tratamiento previo con JAKi y en la terapia de segunda línea para RUX, lo que proporciona beneficios de reducción del agrandamiento del bazo, mejora de los síntomas relacionados con la mielofibrosis y aumento de la independencia de transfusiones en pacientes con riesgo de trombocitopenia por la enfermedad subyacente y la terapia con RUX. Por consiguiente, se describen métodos para tratar neoplasias mieloproliferativas (MPN) como la mielofibrosis. Los métodos pueden incluir la administración de una cantidad con eficacia terapéutica de momelotinib o una sal farmacéuticamente aceptable de este a un sujeto identificado por tener (i) mielofibrosis y (ii) un conteo de plaquetas de menos de 150 x 109/L. Además, se describen métodos que incluyen administrar a un sujeto con mielofibrosis una dosis estable con eficacia terapéutica de momelotinib o una sal farmacéuticamente aceptable de este, durante un período de una pluralidad de semanas, donde el sujeto se evalúa como que mantiene un conteo de plaquetas por encima de un umbral predeterminado de conteo de plaquetas durante el período.
MX2021001985A 2018-08-21 2019-08-21 Metodos agnosticos de conteo de plaquetas para tratar la mielofibrosis. MX2021001985A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862720782P 2018-08-21 2018-08-21
US201862749052P 2018-10-22 2018-10-22
US201862774752P 2018-12-03 2018-12-03
PCT/US2019/047499 WO2020041466A1 (en) 2018-08-21 2019-08-21 Platelet count-agnostic methods of treating myelofibrosis

Publications (1)

Publication Number Publication Date
MX2021001985A true MX2021001985A (es) 2021-04-28

Family

ID=69591359

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001985A MX2021001985A (es) 2018-08-21 2019-08-21 Metodos agnosticos de conteo de plaquetas para tratar la mielofibrosis.

Country Status (13)

Country Link
US (1) US11963962B2 (es)
EP (1) EP3840752A4 (es)
JP (1) JP2022503576A (es)
KR (1) KR20210047308A (es)
CN (1) CN113015527A (es)
AU (1) AU2019324155A1 (es)
BR (1) BR112021002963A2 (es)
CA (1) CA3109291A1 (es)
IL (1) IL280991A (es)
MX (1) MX2021001985A (es)
SG (1) SG11202100962XA (es)
TW (1) TW202021590A (es)
WO (1) WO2020041466A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021102258A1 (en) * 2019-11-22 2021-05-27 Incyte Corporation Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
CN117794545A (zh) * 2021-07-30 2024-03-29 葛兰素史密斯克莱有限责任公司 骨髓纤维化的治疗中的生物标志物和患者选择

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702650C (en) 2007-03-12 2017-01-03 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
NZ611654A (en) * 2010-12-03 2015-08-28 Ym Biosciences Australia Pty Treatment of jak2-mediated conditions
US20150148345A1 (en) * 2013-11-26 2015-05-28 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
WO2015109286A1 (en) * 2014-01-20 2015-07-23 Gilead Sciences, Inc. Therapies for treating cancers
TW202134236A (zh) 2014-06-12 2021-09-16 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
WO2018031579A1 (en) 2016-08-10 2018-02-15 Gilead Sciences, Inc. Momelotinib for treating of acvr1 -mediated diseases

Also Published As

Publication number Publication date
WO2020041466A1 (en) 2020-02-27
SG11202100962XA (en) 2021-03-30
IL280991A (en) 2021-04-29
EP3840752A4 (en) 2022-05-18
US11963962B2 (en) 2024-04-23
CA3109291A1 (en) 2020-02-27
AU2019324155A1 (en) 2021-02-18
TW202021590A (zh) 2020-06-16
JP2022503576A (ja) 2022-01-12
US20210299132A1 (en) 2021-09-30
EP3840752A1 (en) 2021-06-30
BR112021002963A2 (pt) 2021-05-11
KR20210047308A (ko) 2021-04-29
CN113015527A (zh) 2021-06-22

Similar Documents

Publication Publication Date Title
Ahern et al. Pruritus in cutaneous T-cell lymphoma: a review
MX2022011804A (es) Uso de agentes para el tratamiento de condiciones respiratorias.
BR112014018485A8 (pt) Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2021001985A (es) Metodos agnosticos de conteo de plaquetas para tratar la mielofibrosis.
RU2018134167A (ru) Комбинированная терапия для лечения острого миелоидного лейкоза
RU2016149316A (ru) Лечение ревматоидного артрита
WO2022131919A8 (en) Acth in the treatment of an adrenocorticotropic hormone responsive pediatric disorder
HUP0001263A2 (hu) Eljárások anti-CD4OL vegyületek gyógyászati alkalmazásaira
MX2022006083A (es) Metodos para tratar afecciones relacionadas con el receptor s1p1.
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
KR100906086B1 (ko) 활성 물질로서 도코사헥사엔산을 포함하는 지방이상증 치료를 위한 약제학적 조성물
EA202190122A1 (ru) Способы лечения миелофиброза, не зависящие от количества тромбоцитов
RU2003113210A (ru) Лечение раковых заболеваний
JP2018522881A5 (es)
MX2022003982A (es) Metodos de tratamiento de enfermedades relacionadas con el receptor s1p1.
Weinrauch et al. Current therapy of cutaneous leishmaniasis.
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
AU2019287097A1 (en) Pharmaceutical composition for treating chronic constipation
Walker et al. THE MORAL PHILOSOPHICAL CHALLENGES POSED BY FULLY IMPLANTABLE PERMANENT PACEMAKERS.
US20200281928A1 (en) Vitamin b1 in high doses for use in the medical treatment of motor symptoms of some sporadic neurodegenerative diseases, of genetic origin, and of cluster headache and of migraine headache
Haberfellner Myoclonic and generalized tonic clonic seizures during combined treatment with low doses of clozapine and haloperidol
CN108014336B (zh) 一种用于治疗眼自身免疫性葡萄膜炎的药物组合物